Dose escalation and expansion study of lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed with no drug holiday in combination with fulvestrant in patients with HR+/HER2-advanced breast cancer

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Dose escalation and expansion study of lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed with no drug holiday in combination with fulvestrant in patients with HR+/HER2-advanced breast cancer

【24h】

Dose escalation and expansion study of lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed with no drug holiday in combination with fulvestrant in patients with HR+/HER2-advanced breast cancer

机译：Lerociclib（G1T38）的剂量升级和扩展研究，口服CDK4 / 6抑制剂，没有药物假期，与HR + / HER2-先进的乳腺癌患者患者组合

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共3页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词
入库时间 2022-08-20 01:56:10

相似文献

外文文献
中文文献
专利

1. Dose escalation and expansion study of lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed with no drug holiday in combination with fulvestrant in patients with HR+/HER2-advanced breast cancer [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：Lerociclib（G1T38）的剂量升级和扩展研究，口服CDK4 / 6抑制剂，没有药物假期，与HR + / HER2-先进的乳腺癌患者患者组合
2. A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients with PIK3CA-mutant HR+/HER2-breast cancer [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：将突变体选择性Pi3k-α-α-α抑制剂GDC-0077（G）与Letrazole（L）组合的相位IB剂量升级研究与PIK3CA-突变体HR + / HER2-乳腺癌患者的Letrozole（L）组合使用和没有Palbociclib（P）
3. A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer [J] . Campone M., Bachelot T., Penault-Llorca F., Cancer chemotherapy and pharmacology. . 2019,第4期

机译：与雌激素受体阳性和FGFR1 - 扩增或未扩增的转移乳腺癌患者组合尿酸口服尿酸口服施用的IB剂量分配研究
4. Clinical Outcome of Breast and Ovarian Cancer Patients Treated after High-Dose Chemotherapy and Autologous Stem Cell Rescue with Theratope (STn-KLH) Cancer Vaccine: Theratope (STn-KLH) Cancer Vaccine following Autologous Transplant [C] . Leona A. Holmberg, Katherine A. Guthrie, Brenda M. Sandmaier Chemical glycobiology . -1

机译：大剂量化学疗法和自体干细胞拯救治疗的Theratope（STn-KLH）癌症疫苗治疗的乳腺癌和卵巢癌患者的临床结果：自体移植后的Theratope（STn-KLH）癌症疫苗
5. Development of pharmacokinetic-directed dosing of docetaxel in combination with a tyrosine kinase inhibitor for optimization of cancer drug therapy [D] . Pierce, Erica Lynn Bradshaw 2007

机译：与多西他赛结合酪氨酸激酶抑制剂的药代动力学指导剂量的开发，以优化癌症药物治疗
6. Phase 1/1b dose escalation and expansion study of BEZ235 a dual PI3K/mTOR inhibitor in patients with advanced solid tumors including patients with advanced breast cancer [O] . Jordi Rodon, Alejandro PérezFidalgo, Ian E. Krop, -1

机译：BEZ235（PI3K / mTOR双重抑制剂）在晚期实体瘤患者（包括晚期乳腺癌）中的1 / 1b剂量递增和扩展研究
7. Phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with metastatic breast cancer [O] . Mario Campone 2014

机译：含有转移性乳腺癌患者的氟斯坦与尿酸盐的口服施用相IB剂量分配研究

Dose escalation and expansion study of lerociclib (G1T38), an oral CDK4/6 inhibitor, dosed with no drug holiday in combination with fulvestrant in patients with HR+/HER2-advanced breast cancer

著录项

相似文献

相关主题

期刊订阅